Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: A randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes

Pain Medicine (United States)

Volumn 14, Issue 9, 2013, Pages 1332-1345

  Webster, Lynn R ^a   Slevin, Kieran A ^b   Narayana, Arvind ^c   Earl, Craig Q ^d   Yang, Ronghua ^c  

^a CRILifetree Clinical Research   (United States)

^b Virtua Pain and Spine Specialists   (United States)

^c TEVA PHARMACEUTICALS   (Israel)

^d Formerly of Teva Pharmaceuticals   (United States)

Author keywords

Breakthrough Pain; Fentanyl Buccal Tablet; Opioid Tolerant; Oxycodone

Indexed keywords

FENTANYL; MORPHINE; OPIATE; OXYCODONE;

ADULT; ANALGESIA; ARTICLE; BREAKTHROUGH PAIN; CANCER PAIN; CANCER PATIENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATIENT SATISFACTION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TABLET; TREATMENT OUTCOME; TREATMENT RESPONSE;

BREAKTHROUGH PAIN; FENTANYL BUCCAL TABLET; OPIOID TOLERANT; OXYCODONE;

ADMINISTRATION, BUCCAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; BREAKTHROUGH PAIN; CHRONIC PAIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OXYCODONE; PAIN MANAGEMENT; PATIENT SATISFACTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883776682     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12184     Document Type: Article

References (29)

1. Portenoy RK, Hagen NA. Breakthrough pain: Definition, prevalence and characteristics. Pain 1990;41(3):273-281.
2. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: Characteristics and impact in patients with cancer pain. Pain 1999;81(1-2):129-134.
3. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 2000;20(2):87-92.
4. Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: Prevalence and characteristics. J Opioid Manag 2010;6(2):97-108.
5. Portenoy RK, Bennett DS, Rauck R, etal. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain 2006;7(8):583-591.
6. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice. Palliat Med 2001;15(3):243-246.
7. Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003;101(1-2):55-64.
8. Chou R, Fanciullo GJ, Fine PG, etal. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-130.
9. Mercadante S, Radbruch L, Caraceni A, etal. Episodic (breakthrough) pain: Consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002;94(3):832-839.
10. FENTORA [package insert]. Frazer, PA: Cephalon, Inc.; December 2011.
11. Durfee S, Messina J, Khankari R. Fentanyl effervescent buccal tablets: Enhanced buccal absorption. Am J Drug Deliv 2006;4(1):1-5.
12. Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study. Cancer 2009;115(11):2571-2579.
13. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007;5(7):327-334.
14. Simpson DM, Messina J, Xie F, Hale M. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: A multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29(4):588-601.
15. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22(9):805-811.
16. Portenoy RK, Messina J, Xie F, Peppin J. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: A randomized, placebo-controlled study. Curr Med Res Opin 2007;23(1):223-233.
17. Ashburn M, Slevin KA, Messina J, Xie F. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Anesth Analg 2011;112(3):693-702.
18. Farrar JT, Messina J, Xie F, Portenoy RK. A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain. Pain Med 2010;11(9):1313-1327.
19. Fine PG, Messina J, Xie F, Rathmell J. Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: An 18-month study. J Pain Symptom Manage 2010;40(5):747-760.
20. Chou R, Ballantyne JC, Fanciullo GJ, Fine PG. Research gaps on use of opioids for chronic noncancer pain: Findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009;10(2):147-159.
21. International Conference on Harmonisation Working Group. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; June 10, 1996; Washington, DC. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf (accessed September 29, 2012).
22. Dworkin RH, Turk DC, Wyrwich KW, etal. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9(2):105-121.
23. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain 2000;88(3):287-294.
24. Farrar J, Michna E, Messina J, Xie F. A response profile for fentanyl buccal tablet (FBT) in opioid-tolerant patients with breakthrough pain (BTP) [abstract 255]. J Pain 2008;9(4 suppl 2):P39.
25. Stull DE, Narayana A, Burch T, Sandor DW Validation analyses of the patient assessment of function and clinician assessment of patient function in patients with breakthrough pain [poster 354]. Presented at: the 30th Annual Scientific Meeting of the American Pain Society; May 19-21, 2011; Austin, TX.
26. Coluzzi PH, Schwartzberg L, Conroy JD, etal. Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001;91(1-2):123-130.
27. Chou R, Fanciullo GJ, Fine PG, etal. Opioids for chronic noncancer pain: Prediction and identification of aberrant drug-related behaviors: A review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009;10(2):131-146.
28. Passik S, Earl CQ, Yang R Aberrant drug-related behavior observed during a 12-week open-label study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain. Presented at: PAINWeek 2011 National Conference; Las Vegas, NV; September 7-10, 2011.
29. Fine PG, Narayana A, Passik SD. Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: Appropriate patient selection and management. Pain Med 2010;11(7):1024-1036.